Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
A number of other research firms also recently weighed in on RCKT. Chardan Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 7th. Needham & Company LLC raised shares of Rocket Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Wednesday, September 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, November 4th. The Goldman Sachs Group upgraded shares of Rocket Pharmaceuticals from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $3.00 to $4.00 in a research note on Thursday, October 8th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $2.95 price objective on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.77.
Get Our Latest Stock Report on RCKT
Rocket Pharmaceuticals Stock Performance
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03). Equities analysts predict that Rocket Pharmaceuticals will post -1.36 earnings per share for the current fiscal year.
Insider Activity
In related news, General Counsel Martin Wilson sold 75,364 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $3.40, for a total transaction of $256,237.60. Following the completion of the transaction, the general counsel owned 598,489 shares in the company, valued at approximately $2,034,862.60. This trade represents a 11.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 83,160 shares of company stock valued at $277,472. 21.30% of the stock is currently owned by corporate insiders.
Institutional Trading of Rocket Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP acquired a new position in shares of Rocket Pharmaceuticals in the second quarter valued at $28,000. Legal & General Group Plc bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at about $31,000. HB Wealth Management LLC bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at about $36,000. Focus Partners Advisor Solutions LLC bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at about $41,000. Finally, Optiver Holding B.V. lifted its stake in shares of Rocket Pharmaceuticals by 584.1% during the 1st quarter. Optiver Holding B.V. now owns 12,484 shares of the biotechnology company’s stock worth $45,000 after buying an additional 10,659 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients’ cells. The company’s pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy.
Further Reading
- Five stocks we like better than Rocket Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
